AU Patent

AU717743B2 — Nuclear receptor ligands and ligand binding domains

Assigned to University of California · Expires 2000-03-30 · 26y expired

What this patent protects

The present invention provides new methods, particularly computational methods, and compositions for the generation of nuclear receptor synthetic ligands based on the three dimensional structure of nuclear receptors, particularly the thyroid receptor (herein referred to as "T…

USPTO Abstract

The present invention provides new methods, particularly computational methods, and compositions for the generation of nuclear receptor synthetic ligands based on the three dimensional structure of nuclear receptors, particularly the thyroid receptor (herein referred to as "TR"). Also provided are crystals, nuclear receptor synthetic ligands, and related methods.

Drugs covered by this patent

Patent Metadata

Patent number
AU717743B2
Jurisdiction
AU
Classification
—
Expires
2000-03-30
Drug substance claim
No
Drug product claim
No
Assignee
University of California
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.